Despite a sizable gap between the current price and analyst targets, Inhibrx Biosciences operates with deeply impaired fundamentals — free cash flow is negative at over 6,800% of revenue, the company has missed earnings estimates in three of its four most recent consecutive quarters including a miss of nearly 79% in the latest period, and 29% of the float is sold short — making the implied upside contingent on a fundamental transformation not yet visible in reported results.
Thesis pillars
- Catastrophic Cash Burn Quality→Stable
- Three Consecutive Earnings Misses→Stable
- High Short Interest Crowded Bear→Stable
- +1 more pillar — see the Why tab for full reasoning
Inhibrx Biosciences, Inc. (INBX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $97.14: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10 and A.R:R 10.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 30%; Below-average business quality.
Inhibrx Biosciences is a clinical-stage biopharmaceutical company built around two protein-engineered therapeutic candidates, ozekibart (INBRX-109), a tetravalent DR5 agonist for chondrosarcoma and other solid tumors, and INBRX-106, a hexavalent OX40 agonist being studied with... Read more
Sell if holding. Engine safety override at $97.14: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10 and A.R:R 10.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 30%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.3/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 38d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Inhibrx Biosciences, Inc.
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences' lead candidate, ozekibart (INBRX-109), a tetravalent DR5 agonist, met the primary endpoint of its randomized, placebo-controlled ChonDRAgon registrational trial in October 2025, cutting the risk of disease progression or death by 52% in patients with advanced or metastatic chondrosarcoma, and the company plans to submit a Biologics License Application in the second quarter of 2026. Inhibrx's only other clinical program, INBRX-106, a hexavalent OX40 agonist studied alongside Merck's KEYTRUDA, remains in earlier-stage Phase 1/2 testing across several solid tumor types.
Inhibrx generates no product revenue today; historically it has financed operations through equity and debt financings, license and milestone revenue, and grants, reporting $124.2 million in cash and cash equivalents as of December 31, 2025. Ozekibart, engineered as a tetravalent single-domain-antibody agonist of the DR5 apoptosis receptor, is also being studied in Ewing sarcoma (64.5% objective response rate in an evaluable cohort as of January 2026) and colorectal adenocarcinoma (23% objective response rate in a FOLFIRI combination cohort), alongside its chondrosarcoma indication. INBRX-106 pairs a hexavalent OX40 agonist design with Merck's checkpoint inhibitor KEYTRUDA in non-small cell lung cancer and head and neck squamous cell carcinoma. The company relies on third-party CROs and contract manufacturers to run a portion of its clinical trials, preclinical studies, and drug production, and has a loan and security agreement with Oxford Finance LLC that carries restrictive covenants.
Show full overview
Inhibrx's near-term commercial prospects concentrate on a single regulatory submission: with no products on the market and no product revenue to date, the company's plan to file a BLA for ozekibart in chondrosarcoma during the second quarter of 2026 is the event most likely to determine whether Inhibrx generates its first dollar of product revenue. That plan carries execution risk beyond the data itself, since the FDA previously placed the ChonDRAgon trial on partial clinical hold in early 2023 after a fatal hepatotoxicity event, and the 10-K discloses that Inhibrx's operations are concentrated in a single location, exposing both its ongoing INBRX-106 trials and its BLA-preparation work to disruption from a single site-level event such as an earthquake or public health emergency.
See also: Healthcare · Biotechnology
From Inhibrx Biosciences, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-07Recent Developments — Inhibrx Biosciences, Inc.
Latest news
- NEWS Inhibrx Biosciences Says FDA Accepts BLA Seeking Approval Of Ozekibart In Patients With Conventional Chondrosarcoma; PDU — benzinga Jun 15, 2026 positive
- NEWS Inhibrx Biosciences Q1 EPS $(2.15) Misses $(1.79) Estimate — benzinga May 14, 2026 negative
- NEWS Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study — benzinga May 11, 2026 positive
- NEWS Inhibrx Reports Interim Phase 2 Data For INBRX-106 in First-Line HNSCC — benzinga May 11, 2026 positive
- NEWS 12 Health Care Stocks Moving In Friday's After-Market Session — benzinga May 8, 2026 neutral
Generated 2026-07-07T13:21:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineozekibart (INBRX-109) and INBRX-10610-K Item 1A: 'Our two therapeutic candidates are still currently in clinical trials (ozekibart (INBRX-109) and INBRX-106).'
- HIGHGeographicone location10-K Item 1A: 'Our current operations are concentrated in one location, and we or the third parties upon whom we depend may be adversely affected by earthquakes, medical epidemics or pandemics, or other natural disasters.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
5 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 6.6% daily ATR makes tight stops impractical. Position-size conservatively.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $97.14: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10 and A.R:R 10.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 30%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $90.34. Score 4.3/10, moderate confidence.
Take-profit target: $235.88 (+142.8% upside). Prior stop was $90.34. Stop-loss: $90.34.
Concentration risk — Pipeline: ozekibart (INBRX-109) and INBRX-106; Concentration risk — Geographic: one location; Quality below floor (1.8 < 4.0).
Inhibrx Biosciences, Inc. trades at a P/E of N/A (forward -15.5). TrendMatrix value score: 5.0/10. Verdict: Sell.
9 analysts cover INBX with a consensus score of 4.1/5. Average price target: $278.
What does Inhibrx Biosciences, Inc. do?Inhibrx Biosciences is a clinical-stage biopharmaceutical company built around two protein-engineered therapeutic...
Inhibrx Biosciences is a clinical-stage biopharmaceutical company built around two protein-engineered therapeutic candidates, ozekibart (INBRX-109), a tetravalent DR5 agonist for chondrosarcoma and other solid tumors, and INBRX-106, a hexavalent OX40 agonist being studied with KEYTRUDA in solid tumors. Spun off from its former parent in May 2024, the company has no approved products or product revenue; ozekibart's registrational ChonDRAgon trial met its primary endpoint in October 2025, and the company plans to submit a Biologics License Application in the second quarter of 2026.